PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2026International Journal of Urology0 citationsOpen Access

Bayesian Re‐Interpretation of the CheckMate ‐ 9ER Final Analysis: Organ‐Site and IMDC Risk‐Stratified Probabilities of Benefit

View Full Paper
HMHitoshi MasudaSYShugo YajimaHSHiroyuki Sato

Key Points

  • To reinterpret the CheckMate-9ER analysis using a Bayesian approach focusing on organ-site outcomes and IMDC risk.
  • Applied Bayesian statistical methods to analyze CheckMate-9ER data.
  • Stratified analysis based on organ-site and IMDC risk categories.
  • Utilized R programming for data generation and result presentation.
  • Identified distinct probabilities of benefit for different organ sites.
  • Risk stratification enhances prediction of treatment outcomes based on IMDC criteria.
  • Findings support tailored therapeutic strategies based on risk levels.

Abstract

The authors declare no conflicts of interest. Yasuhisa Fujii is a member of the Editorial Board of the International Journal of Urology and the co-authors of this article. To minimize bias, he was excluded from all editorial decision-making related to the acceptance of this article for publication. R code used to generate the results is available from the authors upon reasonable request.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Masuda et al. (2026) studied this question.

synapsesocial.com/papers/69994b88873532290d01faabhttps://doi.org/10.1111/iju.70379
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma2019 · 3,476 citations
  2. 2Bayesian reanalysis of avelumab maintenance therapy in Asian and Japanese patients with advanced urothelial carcinoma: evidence from the JAVELIN Bladder 100 trial2025 · 1 citations
  3. 3Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial2025 · 4 citations
  4. 4Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial2025 · 23 citations
  5. 5Understanding the Differences Between Bayesian and Frequentist Statistics2022 · 104 citations